Eosinophilic Esophagitis Market in India

Eosinophilic Esophagitis in India Trends and Forecast

The future of the eosinophilic esophagitis market in India looks promising, with opportunities in the hospital, retail pharmacy, and online pharmacy markets. The global eosinophilic esophagitis market is expected to reach an estimated $0.4 billion by 2031 with a CAGR of 15.6% from 2025 to 2031. The eosinophilic esophagitis market in India is also forecasted to witness strong growth over the forecast period. The major drivers for this market are the rising awareness of eosinophilic esophagitis, the growing number of cases of food and environmental allergies, and the expanding need for advanced diagnostic equipment for early disease identification and better monitoring.

• Lucintel forecasts that, within the drug type category, proton pump inhibitor is expected to witness the highest growth over the forecast period due to its substantial application to reduce stomach acid production.
• Within the end use category, the hospital is expected to witness the highest growth over the forecast period.

Emerging Trends in the Eosinophilic Esophagitis Market in India

Indian eosinophilic esophagitis (EoE) market is changing rapidly, fueled by technological innovation, patient awareness, and better treatment options. As the disease gains more recognition, the healthcare system in India is focusing more on specialty care and early diagnosis. The trends in the EoE market include advancements in diagnostic equipment, biologic drugs, and patient-centered treatment. These trends are facilitating better management of EoE, leading to more effective and personalized care for patients across the country.

• Advancements in Diagnostic Technologies: Recent advances in diagnostic technologies, including high-resolution endoscopy, biomarker testing, and genetic profiling, are improving the diagnosis of eosinophilic esophagitis in India. These advances allow for earlier and more precise detection, which is critical for effective treatment. By improving differentiation between EoE and other gastrointestinal diseases, these technologies lower the risk of misdiagnosis and underdiagnosis, ultimately improving patient outcomes and treatment efficacy.
• Surge in Biologic Therapies: Biologic treatments, specifically monoclonal antibodies such as dupilumab, are transforming the management of eosinophilic esophagitis in India. These treatments specifically target the immune mechanisms causing inflammation in EoE, which is more targeted than older corticosteroids. With fewer adverse effects, biologic therapy ensures long-term disease control for patients, greatly enhancing their quality of life. The widespread adoption of biologics will drive growth in the Indian market for EoE.
• Enhancing Patient Awareness: Increased awareness of eosinophilic esophagitis among clinicians and the public is one of the major trends in India. Educational programs, including public health campaigns and clinician-specific training programs, are reducing diagnostic delays and misdiagnosis. Greater awareness is prompting more patients to access treatment, thereby creating demand for novel therapies and diagnostic devices. This trend also leads to improved disease control and patient outcomes.
• Telemedicine Integration: Telemedicine is increasingly becoming a part of eosinophilic esophagitis management in India. Through telehealth care, patients can remotely consult specialists and monitor their symptoms, which proves helpful in rural and underserved areas. Clinicians can modify treatment plans in real-time using remote monitoring, enhancing the care process. As telemedicine becomes more integrated into standard healthcare, it should lower healthcare costs and increase access to care for patients across the nation.
• Multidisciplinary Treatment Approaches: There is a growing trend towards multidisciplinary treatment methods for eosinophilic esophagitis in India. These approaches involve interdisciplinary collaboration between specialists such as gastroenterologists, allergists, dietitians, and psychologists. Multidisciplinary care, which addresses both the psychological and physical aspects of the disease, enhances patient outcomes and treatment adherence. As more healthcare centers embrace this model, it is changing how EoE is treated in India, leading to improved patient satisfaction and care.

The new trends in the eosinophilic esophagitis market in India, such as innovations in diagnostic technologies, the growth of biologic therapy, and increased patient focus in treatment, are transforming the EoE care landscape. Improved patient awareness, telemedicine incorporation, and the use of multidisciplinary models of treatment are additional drivers of market growth. These trends are improving disease management and patient outcomes, ultimately shaping the future of EoE care in India.

Recent Developments in the Eosinophilic Esophagitis Market in India

Indian eosinophilic esophagitis (EoE) market has witnessed several recent developments that represent notable advancements in the diagnosis, treatment, and management of the disease. Some key developments include the introduction of new biologic therapies, the evolution of diagnostic techniques, and the increase in telemedicine services. These developments are addressing unmet needs in EoE treatment, providing patients with more options and better outcomes. With growing research investment and regulatory support, the Indian market for EoE treatment is set to expand further.

• Approval of New Biologic Therapies: New biologic therapies like dupilumab have recently been approved by Indian healthcare authorities for the treatment of eosinophilic esophagitis. These therapies target the immune processes underlying the disease, offering a superior and safer option compared to conventional corticosteroids. By providing improved long-term management with fewer side effects, these biologics are significantly enhancing patient outcomes. Their approval is expected to further drive growth in the Indian EoE market, as they provide patients with additional treatment alternatives and enhanced disease management.
• Improvements in Diagnostic Techniques: Recent advances in diagnostic techniques, such as high-resolution endoscopy, non-invasive biomarkers, and genetic profiling, are improving the accuracy and speed of eosinophilic esophagitis diagnosis in India. These technologies enable early detection of the disease, leading to better management and treatment outcomes. They also allow healthcare providers to identify subtypes of the disease, facilitating more customized treatment plans. As diagnostic technology continues to evolve, the market for sophisticated diagnostic equipment is expected to grow.
• Expansion of Specialist Care Centers: The development and growth of specialist treatment centers for eosinophilic esophagitis is another major development in India. These centers consolidate multidisciplinary teams of experts, including gastroenterologists, allergists, dietitians, and mental health specialists, to provide integrated care. The presence of specialist centers improves patient access to expert care, resulting in better EoE management. This development is crucial in ensuring that patients receive coordinated care, which is essential for improving their health outcomes.
• Telemedicine Integration in EoE Care: Telemedicine is slowly becoming an integral component of eosinophilic esophagitis care in India. Consultations, tracking of remote symptoms, and treatment adjustments can now be accessed by patients without having to visit healthcare facilities physically. This is especially beneficial for those living in remote or underserved areas. With greater access to specialists and enhanced medication compliance through real-time monitoring, telemedicine is improving the treatment of EoE. Its adoption is expected to grow further, making care more accessible and affordable.
• Patient Education and Support Programs: Patient support and education programs are becoming an integral part of eosinophilic esophagitis care in India. These programs aim to enhance awareness of the disease, provide diet counseling, and improve treatment compliance. By empowering patients with information and support, these programs can improve compliance with treatment and reduce complications. As these programs expand, they are likely to lead to better disease management and improved patient outcomes.

Recent advances in the Indian eosinophilic esophagitis market, such as the launch of new biologic therapies, innovations in diagnostic techniques, and the integration of telemedicine, are transforming the treatment landscape for EoE. These advancements are providing patients with additional treatment options, enhancing diagnosis, and increasing access to specialist care. As the market continues to develop, these advancements are expected to fuel growth and improve the management of eosinophilic esophagitis in India.

Strategic Growth Opportunities for Eosinophilic Esophagitis Market in India

The Indian eosinophilic esophagitis (EoE) market offers numerous strategic growth opportunities in areas such as pediatric care, personalized medicine, biologic therapies, telemedicine, and multidisciplinary care models. These opportunities are driving the emergence of innovative therapies and improved disease management practices, resulting in better patient outcomes. With a broader understanding of EoE and the introduction of new treatments, the market is poised for strong growth in the coming years.

• Pediatric Eosinophilic Esophagitis Management: Pediatric eosinophilic esophagitis management is an expanding area of opportunity in India. Diagnosing and treating EoE in children at an early age can significantly influence long-term health outcomes, such as growth and development. Tailored treatment plans specific to pediatric patients improve compliance and minimize the risk of complications. With greater emphasis on pediatric care, demand for value-added treatments for children is expected to increase, presenting significant opportunities for both pharmaceutical companies and healthcare providers.
• Personalized Medicine and Biomarker Development: The growth of personalized medicine, driven by biomarkers, is a major opportunity in the Indian eosinophilic esophagitis market. Biomarkers enable clinicians to personalize treatment approaches for individual patients, resulting in more effective and targeted therapies. This approach minimizes side effects and enhances treatment outcomes. As research into biomarkers continues to grow, personalized medicine will play a key role in revolutionizing the treatment paradigm, offering more effective care and better outcomes for patients.
• Biologic Therapies and Targeted Treatments: Biologic therapies, especially monoclonal antibodies, represent a key growth opportunity for the Indian eosinophilic esophagitis market. These drugs address the immune mechanisms behind the disease, offering safer and more efficient treatments compared to traditional medications. With the growing availability of biologics and their proven efficacy in EoE management, the market is expected to expand dramatically. New biologics in development are poised to continue driving market growth, providing patients with more treatment options and improved disease management.
• Remote Care and Telemedicine Solutions: Remote care and telemedicine solutions are emerging growth opportunities in the Indian eosinophilic esophagitis market. With remote consultations, symptom monitoring, and real-time adjustments to treatment plans, telemedicine offers an efficient and accessible method for managing EoE. This is particularly useful for rural and underserved patients who may lack full access to specialists. As telemedicine adoption increases, it is expected to enhance patient satisfaction, improve treatment compliance, and reduce healthcare costs.
• Multidisciplinary Care Approach for EoE: The shift towards multidisciplinary care for eosinophilic esophagitis offers a substantial growth opportunity in India. Involving specialists from various fields such as gastroenterology, immunology, allergy, and nutrition ensures holistic treatment tailored to the individual patient. This approach improves disease management, enhances patient outcomes, and results in a better quality of life. As more hospitals and clinics adopt this model, the demand for multidisciplinary care will increase, further driving market growth.

Strategic growth drivers in the Indian eosinophilic esophagitis market, such as pediatric care, personalized medicine, biologic therapies, telemedicine, and multidisciplinary treatment models, are expected to fuel strong market growth. These opportunities are improving disease management and patient outcomes while opening new areas of exploration for healthcare providers and pharmaceutical companies. As these trends evolve, they will shape the future of EoE treatment in India.

Eosinophilic Esophagitis Market in India Driver and Challenges

The Indian eosinophilic esophagitis (EoE) market is influenced by various technological, economic, and regulatory drivers and challenges. Key drivers include improvements in diagnostic and therapy technologies, increasing patient awareness, and better access to healthcare services. However, the market is also challenged by high treatment costs, inadequate healthcare infrastructure, and limited specialized care in rural areas. Understanding these drivers is essential to addressing the unmet medical needs of patients.

The factors responsible for driving the eosinophilic esophagitis market in India include:
• Advances in Diagnostic Technology: Emerging diagnostic technologies, such as high-resolution endoscopy and genetic screening, are driving growth in the Indian eosinophilic esophagitis market. These advances enable early and accurate diagnosis of EoE, which leads to better treatment outcomes. By reducing the risk of misdiagnosis and offering more precise treatment options, these technologies improve patient outcomes and increase demand for specialized treatment and diagnostic equipment.
• Increased Patient Awareness: Growing awareness of eosinophilic esophagitis among physicians and the general public is a key catalyst for the Indian market. Public health initiatives, awareness programs, and educational campaigns are helping reduce diagnostic delays and encouraging more patients to seek treatment. As awareness grows, demand for diagnostic and therapeutic products is expected to rise, further driving market growth.
• Government Support and Regulatory Approvals: Government programs and regulatory approvals for new therapies are supporting growth in the eosinophilic esophagitis market. The approval of biologic drugs, such as dupilumab, has expanded treatment options and provided safer and more effective alternatives to traditional medications. Additionally, regulatory agencies are promoting research and development in EoE, encouraging pharmaceutical companies to invest in the market and introduce new solutions.
• Enhanced Access to Healthcare Services: Growth in healthcare services, particularly in rural India, is boosting the eosinophilic esophagitis market. The availability of specialized care and treatment in previously underserved areas is improving access to diagnosis and management. As healthcare infrastructure continues to grow, more patients will receive timely and effective treatment, driving greater market demand.
• Biologic Therapy Adoption: The increasing use of biologic treatments for eosinophilic esophagitis is a major driver in the Indian market. Biologic treatments target the underlying immune response, offering more effective and safer solutions compared to traditional corticosteroids. As biologic treatments become more accessible and receive approval for wider use, they are expected to dominate the treatment landscape, improving long-term care for patients and reducing the need for invasive procedures.

Challenges in the eosinophilic esophagitis market in India are:
• High Treatment Costs: Despite advancements in treatment, the high cost of biologic therapies remains a significant challenge in the Indian eosinophilic esophagitis market. These drugs are expensive for most patients, particularly those in lower-income areas. This cost barrier limits the widespread adoption of biologics, restricting access to effective treatment for many individuals.
• Insufficient Healthcare Infrastructure in Rural Areas: The lack of advanced healthcare facilities in rural areas presents an obstacle to proper EoE management in India. Many rural patients struggle to access specialized treatment and diagnostic services, which leads to delays in diagnosis and compromised treatment outcomes.
• Fragmented Treatment Approach: A fragmented approach to EoE care in India is another challenge. The lack of coordination among various specialists can lead to delays in treatment and missed opportunities for optimal care. A more integrated, multidisciplinary approach is needed to address all aspects of EoE management, but its adoption has been slow.

Key drivers of the eosinophilic esophagitis market in India, such as technological innovation, increasing patient awareness, government incentives, improved access to healthcare, and the adoption of biologic therapies, are positively influencing market growth. However, challenges such as high treatment costs, limited healthcare infrastructure in rural areas, and fragmented care delivery are constraining the effectiveness of treatments. Overcoming these challenges will be essential for realizing the full potential of the market and ensuring better outcomes for EoE patients in India.

List of Eosinophilic Esophagitis Market in India Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, eosinophilic esophagitis companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the eosinophilic esophagitis companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10

Eosinophilic Esophagitis Market in India by Segment

The study includes a forecast for the eosinophilic esophagitis market in India by drug type and end use.

Eosinophilic Esophagitis Market in India by Drug Type [Analysis by Value from 2019 to 2031]:

• Corticosteroids
• Proton Pump Inhibitor
• Late Stage Pipeline Drugs

Eosinophilic Esophagitis Market in India by End Use [Analysis by Value from 2019 to 2031]:

• Hospital
• Retail Pharmacies
• Online Pharmacies

Features of the Eosinophilic Esophagitis Market in India

Market Size Estimates: Eosinophilic esophagitis in India market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Eosinophilic esophagitis in India market size by drug type and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different drug types and end uses for the eosinophilic esophagitis in India.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the eosinophilic esophagitis in India.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What are the major drivers influencing the growth of the eosinophilic esophagitis market in India?
Answer: The major drivers for this market are the rising awareness of eosinophilic esophagitis, the growing number of cases of food and environmental allergies, and the expanding need for advanced diagnostic equipment for early disease identification and better monitoring.
Q2. What are the major segments for eosinophilic esophagitis market in India?
Answer: The future of the eosinophilic esophagitis market in India looks promising with opportunities in the hospital, retail pharmacy, and online pharmacy markets.
Q3. Which eosinophilic esophagitis market segment in India will be the largest in future?
Answer: Lucintel forecasts that proton pump inhibitor is expected to witness highest growth over the forecast period due to its substantial application to reduce stomach acid production.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 10 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the eosinophilic esophagitis market in India by drug type (corticosteroids, proton pump inhibitor, and late stage pipeline drugs) and end use (hospital, retail pharmacies, and online pharmacies)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Eosinophilic Esophagitis Market in India, Eosinophilic Esophagitis Market in India Size, Eosinophilic Esophagitis Market in India Growth, Eosinophilic Esophagitis Market in India Analysis, Eosinophilic Esophagitis Market in India Report, Eosinophilic Esophagitis Market in India Share, Eosinophilic Esophagitis Market in India Trends, Eosinophilic Esophagitis Market in India Forecast, Eosinophilic Esophagitis Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.